Nhua Pharmaceutical's investee Haoxinqing plans to bring in 262 million yuan in capital increase, stepping up AI psychological companion robots

财中社··CN·Read original
2▲1 ▼0Impact / 5
Summary · why it matters

Nhua Pharmaceutical announced on September 29 that its investee Haoxinqing plans to raise 262 million yuan by issuing 7.77 million shares, bringing in seven new shareholders: Anjiemude, Imeik, Wuxi Dingqi, Zhangzhou Jiulongjiang, Zhangzhou Gaoxin, Shanjin Asset Management, and Unifuture. Nhua Pharmaceutical waived its preemptive right to subscribe in this capital increase, and its shareholding will fall from 19.10% to 18.04%, while it remains the largest shareholder of Haoxinqing. Haoxinqing is an AI-driven mental health and medical technology group, with businesses covering digital healthcare, a network of psychiatric and psychological doctors, offline specialty clinics, corporate mental health services, and AI technology solutions. The funds raised this time will be used mainly for AI psychological companion robots, diagnostic technology, and the digitalization of the psychological and medical health industry. In the first half of 2026, Nhua Pharmaceutical achieved revenue of 3.218 billion yuan and net profit attributable to the parent of 741 million yuan.

Impact on assets 2

Others▲ · 2 stocks
Jiangsu Nhwa Pharmaceutical Co Ltd
002262
± MixedCapitalrelevance

Nhwa waives its preemptive right in Haoxinqing's 262M yuan capital increase, diluting its stake from 19.10% to 18.04% while remaining largest shareholder.

Off-coverage companies 7

GoodMood Holdings LimitedPrivate± Mixed
relevance

安杰睦德Private± Mixed
relevance

山金资产管理Private± Mixed
relevance

无锡鼎祺Private± Mixed
relevance

江苏好欣晴移动医疗科技有限公司Private± Mixed
relevance

漳州市九龙江集团有限公司Private± Mixed
relevance

漳州高鑫Private± Mixed
relevance

© 2026 MarketIVNews